Building a Synthetic Biology Platform

CB Therapeutics aims to become a leader in research, development and production of yeast-based tryptamine, cannabinoids and their analogs.

Download the investor presentation, receive an IPO alert, and subscribe to corporate updates.

Investment Highlights

Unique Economics

Experienced Team

Blue-Sky Potential

Low cost, high purity, environmentally-friendly production in just days.

Management team with a passion for science and a knack for business.

New molecules, IP development, and licensing opportunities.

Robust & Growing Pipeline



Numerous letters of intent worth millions of dollars for various cannabinoids in its pipeline.

Memorandum of Understanding with the Cleveland Clinic to support clinical trials.

Copyright © 2020. All rights reserved.